¹⁸F-florbetaben whole-body PET/MRI for evaluation of systemic amyloid deposition.

ABSTRACT:

Background

Florbetaben, a ¹⁸F-labeled stilbene derivative (Neuraceq®, formerly known as BAY-949172), is a diagnostic radiopharmaceutical developed to visualize β-amyloid plaques in the brain. Here, we report a pilot study evaluating patients with suspected cardiac amyloidosis for systemic extent of disease.

Methods

We prospectively enrolled nine patients, 61-86 year old (mean ± SD 69.4 ± 8.6), referred from the cardiac amyloid clinic. First, dynamic imaging of the heart was acquired immediately after injection of 222-318.2 MBq (mean ± SD 270.1 ± 33.3) of ¹⁸F-florbetaben using the GE SIGNA PET/MRI. This was followed by a whole-body PET/MRI scan 60-146.4 min (mean ± SD 98 ± 33.4) after injection. Cardiac MRI sequences included ECG-triggered cine SSFP, T2-

SUBMITTER: Baratto L 

PROVIDER: S-EPMC6057864 | biostudies-literature | 2018 Jul

REPOSITORIES: biostudies-literature